Abstract
Oxidative stress, one of the crucial factors of genomic instability, is involved in many illnesses - from DNA damage and repair (DDR) related diseases to neurological abnormalities and cancer. Patients with defective DDR pathways display high level of cancer predisposition and at the same time - reveal hydrocephalia, dementias and even diabetes mellitus - all representing common hallmarks of mitochondria-related disorders. Since mitochondria are responsible both for the cell energetic metabolism and for reactive oxygen/nitrogen species (RO/NS) formation, mitochondrial dysfunction (MDF) play a pivotal role in the above disorders. Not surprisingly, RO/NS are considered to be a primary target for a large spectrum of compounds aiming to eliminate these adverse species or, in contrary, enhance their presence in order to amplify cellular death pathways. Yet, only few chemicals have received medical appreciation mainly because of their questionable therapeutic values in healthy states. As a result, recent efforts have been focused on finding the drugs that improve mitochondrial functions or chemoprevent MDF rather than being applied as RO/NS scavengers. This review addresses the most recent progress in the development and application of such chemicals and outlines some future perspectives.
Keywords: Apoptosis, chemoprevention, mitochondria, mitophagy, oxidative stress, RNS, ROS.
Current Medicinal Chemistry
Title:Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Volume: 22 Issue: 26
Author(s): Alex Lyakhovich and Dmitri Graifer
Affiliation:
Keywords: Apoptosis, chemoprevention, mitochondria, mitophagy, oxidative stress, RNS, ROS.
Abstract: Oxidative stress, one of the crucial factors of genomic instability, is involved in many illnesses - from DNA damage and repair (DDR) related diseases to neurological abnormalities and cancer. Patients with defective DDR pathways display high level of cancer predisposition and at the same time - reveal hydrocephalia, dementias and even diabetes mellitus - all representing common hallmarks of mitochondria-related disorders. Since mitochondria are responsible both for the cell energetic metabolism and for reactive oxygen/nitrogen species (RO/NS) formation, mitochondrial dysfunction (MDF) play a pivotal role in the above disorders. Not surprisingly, RO/NS are considered to be a primary target for a large spectrum of compounds aiming to eliminate these adverse species or, in contrary, enhance their presence in order to amplify cellular death pathways. Yet, only few chemicals have received medical appreciation mainly because of their questionable therapeutic values in healthy states. As a result, recent efforts have been focused on finding the drugs that improve mitochondrial functions or chemoprevent MDF rather than being applied as RO/NS scavengers. This review addresses the most recent progress in the development and application of such chemicals and outlines some future perspectives.
Export Options
About this article
Cite this article as:
Lyakhovich Alex and Graifer Dmitri, Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs, Current Medicinal Chemistry 2015; 22 (26) . https://dx.doi.org/10.2174/0929867322666150729114036
DOI https://dx.doi.org/10.2174/0929867322666150729114036 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Test Your Memory (TYM) Test Outperforms the MMSE in the Detection of MCI and Dementia
Current Alzheimer Research Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition
Current Medicinal Chemistry Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Conference Report: 9th Clinical Trials on Alzheimer's Disease (CTAD): Marriott Marquis San Diego Marina, San Diego, CA, USA December 8-10, 2016
CNS & Neurological Disorders - Drug Targets Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Long-term Reproductive and Metabolic Consequences of PCOS
Current Diabetes Reviews Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Current Drug Safety Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Other Anti- Inflammatory Agents in the Treatment of Neurodegenerative Disease
Current Alzheimer Research Repetitive Transcranial Magnetic Stimulation Reverses Aβ1–42-induced Dysfunction in Gamma Oscillation during Working Memory
Current Alzheimer Research Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels
Current Alzheimer Research Editorial (Thematic Issue: Cognitive Dysfunction in Major Depressive Disorder - Pathophysiology, Clinical Implications and Treatment Opportunities)
CNS & Neurological Disorders - Drug Targets BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Current Enzyme Inhibition Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy